STOCK TITAN

9 Meters Biopharma to Participate in the 2022 BIO International Convention

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

9 Meters Biopharma (NASDAQ: NMTR) announced its participation in the 2022 BIO International Convention from June 13-16 in San Diego, CA. This event aligns with the company's strategy to seek partners for developing its advanced treatments: vurolenatide for short bowel syndrome and larazotide for celiac disease. The BIO Convention is the largest biotechnology gathering globally, hosting over 15,000 leaders in the biopharmaceutical sector. 9 Meters aims to leverage this platform for networking and partnering opportunities.

Positive
  • None.
Negative
  • None.

RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 2022, in San Diego, California.

Attendance at the 2022 BIO International Convention is aligned with the Company's strategy to secure partners for the global and/or regional development and future commercialization of its advanced development stage assets, vurolenatide for short bowel syndrome and larazotide for celiac disease. Members of the 9 Meters management team will be participating in one-on-one partnering meetings throughout the conference.

The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world's largest industry gathering and brings together over 15,000 global biotechnology and biopharmaceutical leaders. The four-day, in-person event includes networking, programming, and partnering opportunities.

About 9 Meters Biopharma
9 Meters Biopharma, Inc., is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. 9 Meters is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several near clinical-stage assets.

For more information please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Forward-Looking Statements
This press release includes forward-looking statements based upon 9 Meters' current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones, and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: uncertainties associated with the clinical development and regulatory approval of product candidates; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; risks related to the inability of 9 Meters to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs, including in light of current stock market conditions; risk of delisting from Nasdaq; reliance on collaborators; reliance on research and development partners; risks related to cybersecurity and data privacy; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in 9 Meters' Annual Report on Form 10-K for the year ended December 31, 2021, and in other filings that 9 Meters has made and future filings 9 Meters will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. 9 Meters expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Corporate Contact
Al Medwar
SVP, Investor Relations & Corporate Communications
9 Meters Biopharma, Inc.
investor-relations@9meters.com

Media Contact
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626

SOURCE: 9 Meters Biopharma, Inc.



View source version on accesswire.com:
https://www.accesswire.com/704944/9-Meters-Biopharma-to-Participate-in-the-2022-BIO-International-Convention

FAQ

What is 9 Meters Biopharma's purpose at the 2022 BIO International Convention?

9 Meters Biopharma aims to secure partners for the global development and commercialization of its treatments, vurolenatide and larazotide.

When is the 2022 BIO International Convention being held?

The 2022 BIO International Convention takes place from June 13-16, 2022.

Where is the 2022 BIO International Convention located?

The convention is held in San Diego, California.

What diseases does 9 Meters Biopharma focus on treating?

9 Meters focuses on rare digestive diseases, specifically targeting short bowel syndrome and celiac disease.

Which treatments is 9 Meters Biopharma showcasing at the convention?

The company is showcasing vurolenatide for short bowel syndrome and larazotide for celiac disease.

NMTR

NASDAQ:NMTR

NMTR Rankings

NMTR Latest News

NMTR Stock Data

1.04M
Computer Storage Device Manufacturing
Manufacturing
Link
US
Raleigh